We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

By LabMedica International staff writers
Posted on 17 Oct 2024

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. More...

Scientists have been working hard to make diagnostic testing more accessible, especially for individuals in rural areas or developing countries, and for those who fear needles when it comes to blood tests. Existing rapid tests, known as lateral-flow assays, such as COVID tests or pregnancy tests, can quickly indicate a "yes" or "no" regarding the presence of a specific biomarker or biomolecule in blood or urine. However, these tests usually cannot quantify how much of the substance is present and often lack the sensitivity to detect very low amounts. On the other hand, the gold standard for clinical blood tests, the enzyme-linked immunosorbent assay (ELISA), is highly sensitive and specialized enough to identify rare or scarce biomarkers. However, it requires costly equipment and complex procedures, leading to delays of hours or days before patients receive their results. But all that could now change with the introduction of a new handheld, sound-based diagnostic system that can provide accurate results in just an hour using only a small finger prick of blood.

Based on systematic experiments and peer-reviewed research, researchers at the University of Colorado Boulder (Boulder, CO, USA) are developing a diagnostic tool that is sensitive, portable, and user-friendly. Their innovative components include tiny particles referred to as “functional negative acoustic contrast” particles (fNACPs) and a custom-built handheld device known as an “acoustic pipette,” which emits sound waves to the blood samples. The fNACPs, which resemble cell-sized rubber balls, are engineered with functional coatings that enable them to recognize and capture a specific biomarker of interest, such as an infectious virus or a protein associated with a potential health issue. These particles respond to sound wave pressure differently than blood cells, and the acoustic pipette is designed to take advantage of this unique response.

When a small blood sample is combined with the custom particles and placed into the acoustic pipette, sound waves push the particles to the side of a chamber where they are trapped, allowing the rest of the blood to be flushed away. The remaining biomarkers attached to the particles are then tagged with fluorescent markers and illuminated with lasers to quantify their presence. This entire process takes less than 70 minutes and is within a device small enough to fit in the palm of a hand. The pipette and particle system, detailed in a new paper published in the journal Science Advances, shows that it can provide the same level of sensitivity and specificity as a gold-standard clinical test while simplifying the workflow significantly. Future enhancements could further decrease testing time, enabling blood diagnostics to be conducted right at the patient’s bedside. This could be particularly beneficial for determining whether a patient has an infectious disease, assessing their viral load, and monitoring how quickly it increases. Additionally, the device could potentially be used to measure antibodies to establish the need for booster shots, test for allergies, or detect proteins linked to certain cancers.

“We’ve developed a technology that is very user-friendly, can be deployed in various settings, and provides valuable diagnostic information in a short time frame,” said senior author Wyatt Shields, assistant professor in the Department of Chemical and Biological Engineering at CU Boulder. “We think this has a lot of potential to address some of the longstanding challenges that have come from having to take a blood sample from a patient, haul it off to a lab and wait to get results back.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Thyroid Test
Anti-Thyroid EIA Test
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.